Darolutamide: First Approval
- 72 Downloads
Darolutamide (NUBEQA™) is a structurally distinct non-steroidal androgen receptor antagonist being developed by Orion and Bayer as a treatment for prostate cancer. Based on positive results in the phase III ARAMIS trial, darolutamide was recently approved in the USA for the treatment of men with non-metastatic castration-resistant prostate cancer. This article summarizes the milestones in the development of darolutamide leading to this first approval.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis International Ltd/Springer Nature, and S. Duggan, a salaried employee of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.
- 2.US Food & Drug Administration. FDA approves darolutamide for non-metastatic castration-resistant prostate cancer [media release]. 1 Aug 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer.
- 3.Bayer. Bayer submits European marketing authorization application for darolutamide [media release]. 8 Mar 2019. http://www.bayer.com.
- 4.Orion. Darolutamide submitted for marketing authorization in Japan [media release]. 5 Mar 2019. http://www.orion.fi.
- 5.Bayer HealthCare Pharmaceuticals Inc. Nubeqa™ (darolutamide): US prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf. Accessed 19 Aug 2019.
- 6.Orion. Orion group interim report January-September 2013 [media release]. 22 Oct 2013. http://www.orion.fi.
- 7.Bayer. Bayer and Orion Corporation to develop and commercialize novel prostate cancer treatment [media release]. 2 Jun 2014. http://www.bayerpharma.com.
- 8.Bayer. Bayer and Orion expand clinical development program for BAY-1841788 (ODM-201) in prostate cancer [media release]. 3 Jun 2016. http://www.bayer.us.
- 12.Shore N, Zurth C, Fricke R, et al. Evaluation of clinically relevant drug–drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol. 2019. https://doi.org/10.1007/s11523-019-00674-0.CrossRefPubMedGoogle Scholar
- 18.Gillessen S, Hayoz S, Fuhrer AC, et al. A phase 2 trial of ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a AR targeting agent and nonprogressive on a second line taxane (SAKK 08/16) [abstract no. TPS393]. J Clin Oncol. 2018;36(6 Suppl).Google Scholar
- 19.Tombal BF, Gillessen S, Loriot Y, et al. Intergroup study EORTC-1532-gucg: a phase 2 randomized open-label study of oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancer (PCa) [abstract no. TPS406]. J Clin Oncol. 2018;36(6 Suppl).CrossRefGoogle Scholar
- 20.Alliance for Clinical Trials in Oncology. ARACOG: Phase II study of androgen receptor and cognitive function in patients treated with darolutamide or enzalutamide. 2019. https://www.allianceforclinicaltrialsinoncology.org. Accessed 30 Sep 2019.
- 21.Us TOO International. August 2019 Hot Sheet. 2019. https://www.ustoo.org/Read-the-HotSheet-Newsletter. Accessed 30 Sept 2019.